Jefferies Financial Group Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price

Compass Therapeutics (NASDAQ:CMPX) had its target price lifted by Jefferies Financial Group from $7.00 to $8.00 in a research note released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued reports about the stock. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Compass Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $11.17.

Compass Therapeutics Trading Up 11.4 %

Shares of NASDAQ:CMPX opened at $3.90 on Monday. The stock has a fifty day simple moving average of $2.12 and a two-hundred day simple moving average of $1.74. Compass Therapeutics has a 12-month low of $0.76 and a 12-month high of $4.07. The stock has a market capitalization of $536.60 million, a price-to-earnings ratio of -10.54 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, equities research analysts predict that Compass Therapeutics will post -0.35 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC raised its position in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares during the period. Barclays PLC increased its holdings in Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares in the last quarter. Renaissance Technologies LLC raised its stake in Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after acquiring an additional 70,200 shares during the period. Catalina Capital Group LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth $71,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Compass Therapeutics during the 3rd quarter valued at $79,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.